Hepatix

HepaTx is a preclinical-stage biotechnology company focused on developing regenerative medicine solutions for late-stage liver disease. The company's core technology platform enables the conversion of adipose-derived mesenchymal stem cells into functional hepatocytes, providing a potential alternative to whole-organ transplantation. By utilizing a patient's own fat cells or healthy donor cells, HepaTx aims to address the critical shortage of donor livers and offer a less invasive treatment for metabolic and chronic liver conditions. Their lead candidate, HTX-101, is being developed for indications including Urea Cycle Disorders and Alpha-1 Antitrypsin Deficiency. Headquartered in San Carlos, California, the company leverages research originating from Stanford University to advance its cell therapy pipeline.